|
Cohort1: dose level 1
|
| Administration route |
intratumoral injection |
| Dosage |
0.5 mg/mL (up to 4 tumor sites), one cycle on Days 1, 5, and 8, up to 5 cycles |
| Pts |
30 |
| Age |
Adult, Older_Adult |
| Outcome |
9/28(ORR) |
| Adverse reactions |
2/30(Musculoskeletal and connective tissue disorders; Nervous system disorders) |
| References |
PMID:
31852717
|
|
|
Cohort2: dose level 2
|
| Administration route |
intratumoral injection |
| Dosage |
0.5 mg/mL (up to 4 tumor sites), one cycle on Days 1, 8, and 15, up to 9 cycles |
| Pts |
17 |
| Age |
Adult, Older_Adult |
| Outcome |
4/16(ORR) |
| Adverse reactions |
3/17(Infections and infestations; Nervous system disorders; Respiratory, thoracic and mediastinal disorders) |
| References |
PMID:
31852717
|
|
|
Cohort3: dose level 3
|
| Administration route |
intratumoral injection |
| Dosage |
0.5 mg/mL (up to 4 tumor sites), one cycle on Days 1, 5, and 8, up to 2 cycles |
| Pts |
4 |
| Age |
Adult, Older_Adult |
| Outcome |
1/4(ORR) |
| Adverse reactions |
No serious clinical adverse events |
| References |
PMID:
31852717
|
|